A study into Alzheimer’s has revealed hugely promising results, scientists have announced.
The investigation tested a new drug – called lecanemab – against a placebo, and found that those who received the drug had a 27% slower rate of cognitive decline than those who received the placebo.
The study was run by Biogen, a biotech company specialising in neuroscience, and Eisai, a pharmaceutical company, who have high hopes for the results.
Lecanemab, co-developed by Biogen and Eisai, has been developed to help remove plaque from the brain, which is what many scientists believe causes Alzheimer’s. It was found to move this plaque and progress was seen in many of the patients by the sixth month of the 18-month study, according to the report.
“The positive result of the lecanemab … is an important milestone for Eisai in fulfilling our mission to meet the expectations of the Alzheimer’s disease community,” said Haruo Naito, Chief Executive Officer at Eisai, in a statement.
“Alzheimer’s disease not only presents a great challenge for patients and their families, but it also negatively impacts society, including decreased productivity, increased social costs and disease-related anxiety. We believe that helping to alleviate these burdens will positively impact society as a whole.”
Inspired to act?
DONATE: Give to Alzheimer’s Research to help fund studies into treating and curing Alzheimer’s.
GET INSPIRED: Volunteer with the Alzheimer’s Society to help support those suffering from Alzheimer’s and their families.